
Narcolepsy’s Lost Signal Gets Restored: FDA Approves First Orexin-Targeting Drug
For people with narcolepsy type 1, treatment has long been a patchwork: stimulants to hold off daytime sleepiness, sodium oxybate to soften cataplexy, antidepressants for hallucinations and sleep paralysis. None of them touched the root of the problem. On Aug. 5, 2026, that changed. The U.S. Food and Drug Administration approved Orzeyful (oveporexton), an oral […]










